Propitious Development of Vaccines for SARS-CoV
Pp. 42-75 (34)
Anti-infective agents are effective for controlling infectious diseases by
killing or inhibiting infectious organisms. Anti-infective agent encompasses antibiotics,
antifungal agents and antiviral agents, etc. In this category, vaccines are major
contributors in recent years to preventing infectious diseases. The emergence of
COVID-19 (COronaVIrus Disease 2019) pandemic has caused a resurgence of interest
in finding new vaccines. The vaccines are generally classified into conventional
vaccines and recombinant vaccines. In this context, the recent development of Vaccines
for SARS-CoV (Severe Acute Respiratory Syndrome Coronavirus) has to be focussed.
SARS-CoV is a human virus that comes under the order of Nidovirales and the family
of Coronaviridae. This virus primarily causes respiratory diseases by targeting ACE-2
(angiotensin-converting enzyme 2) receptor. This virus is categorized into SARSCoV-
1 and SARS-CoV-2 (COVID-19). In this essence, the contents embrace the
various aspects regarding the common vaccine development pipeline, importance of
vaccination for prevention of infectious diseases, types of vaccine production methods
that are implemented for SARS-CoV virus categories, potential targets for SARS-CoV
vaccines, difficulties or feasibilities involved in vaccine production, phases
accomplished in vaccine production and involvement of vaccines in addressing the
global pandemic. In conclusion, this chapter confers the outline of vaccine progression
marked up-to-date for SARS-CoV.
ACE-2 receptor, Animal model, COVID-19 vaccine, Nucleocapsid
Protein, RBD, Respiratory failure, SARS-CoV, Spike protein, Vaccine development.